Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. | Director | Common Stock | 31.5K | $12.3K | $0.39 | Jun 23, 2022 | Direct |
Cerevel Therapeutics Holdings, Inc. | President & CEO, Director | Common Stock | 0 | $0 | $41.18 | Aug 1, 2024 | By Trust |
Cerevel Therapeutics Holdings, Inc. | President & CEO, Director | Common Stock | 0 | $0 | $41.18 | Aug 1, 2024 | Direct |
Cerevel Therapeutics Holdings, Inc. | President & CEO, Director | Performance-based Restricted Stock Units | 0 | $0 | $41.18 | Aug 1, 2024 | Direct |
Cerevel Therapeutics Holdings, Inc. | President & CEO, Director | Restricted Stock Units | 0 | $0 | $41.18 | Aug 1, 2024 | Direct |
Atara Biotherapeutics, Inc. | Director | Non-Qualified Stock Option (Right to Buy) | 31.5K | Jun 23, 2022 | Direct | ||
Upstream Bio, Inc. | Director | Stock Option (Right to Buy) | 17.1K | Oct 10, 2024 | Direct | ||
Ikena Oncology, Inc. | Director | Stock Option (Right to Buy) | 13.4K | Jun 9, 2022 | Direct | ||
Cerevel Therapeutics Holdings, Inc. | President & CEO, Director | Stock Option (Right to Buy) | 0 | Aug 1, 2024 | Direct | ||
Translate Bio, Inc. | Chief Executive Officer, Director | Common Stock | 0 | $38.00 | Sep 14, 2021 | By Ronald C. Renaud, Jr. Trust - 2007 | |
Translate Bio, Inc. | Chief Executive Officer, Director | Common Stock | 0 | $38.00 | Sep 14, 2021 | By Ronald Renaud 2014 Irrevocable Family Trust | |
Translate Bio, Inc. | Chief Executive Officer, Director | Common Stock | 0 | $38.00 | Sep 14, 2021 | Direct | |
Translate Bio, Inc. | Chief Executive Officer, Director | Stcok Option (right to buy) | 0 | Sep 14, 2021 | Direct | ||
Translate Bio, Inc. | Chief Executive Officer, Director | Stock Option (right to buy) | 0 | Sep 14, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
UPB | Upstream Bio, Inc. | Oct 10, 2024 | 1 | $0 | 4 | Oct 15, 2024 | Director |
UPB | Upstream Bio, Inc. | Oct 10, 2024 | 0 | $0 | 3 | Oct 10, 2024 | Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Aug 1, 2024 | 5 | $0 | 4 | Aug 5, 2024 | President & CEO, Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Jan 19, 2024 | 1 | $0 | 4 | Jan 23, 2024 | President & CEO, Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Dec 19, 2023 | 2 | $0 | 4 | Dec 21, 2023 | President & CEO, Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Aug 3, 2023 | 1 | $2.01M | 4 | Aug 7, 2023 | President & CEO, Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Jun 12, 2023 | 3 | $0 | 4 | Jun 14, 2023 | President & CEO, Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Jun 12, 2023 | 0 | $0 | 3 | Jun 14, 2023 | President & CEO, Director |
ATRA | Atara Biotherapeutics, Inc. | Jun 23, 2022 | 2 | $0 | 4 | Jun 27, 2022 | Director |
IKNA | Ikena Oncology, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 13, 2022 | Director |
IKNA | Ikena Oncology, Inc. | Dec 21, 2021 | 1 | $0 | 4 | Dec 23, 2021 | Director |
TBIO | Translate Bio, Inc. | Sep 14, 2021 | 8 | -$36.3M | 4 | Sep 14, 2021 | Chief Executive Officer, Director |
ATRA | Atara Biotherapeutics, Inc. | Jun 8, 2021 | 2 | $0 | 4 | Jun 9, 2021 | Director |
TBIO | Translate Bio, Inc. | Apr 7, 2021 | 2 | $66.7K | 4/A | Sep 14, 2021 | Chief Executive Officer, Director |